Small Molecules, Big Insights™
Global Leader in Metabolomics
Metabolon helps researchers measure small molecules that reflect health, disease, nutrition, the microbiome, the environment, and more. Our solutions deliver clear, actionable insights that give biological context to complex data.
Celebrating 25 Years of Discovery
For 25 years, Metabolon has driven innovation in metabolomics, and pioneered best practices in biochemical profiling. This evolution has delivered high-quality data to our clients that have enabled deeper insights and supported impactful scientific discoveries. With a strong commitment to scientific excellence and client success, Metabolon has powered the business of science and set a high standard for quality and trust in metabolomics research.
As we celebrate this milestone, we honor the scientists, collaborators, and partners who have made it possible. Together, we’ve uncovered novel biomarkers, identified molecules not known to exist, advanced clinical breakthroughs, and reshaped how the world understands biology. The future of scientific discovery is brighter because of the last 25 years—and we’re just getting started.
Company History
Explore our milestones that have marked our growth and commitment to innovation and discovery.
Metabolon is Founded
Metabolon was founded in 2000 by John Ryals, Ph.D. and Paul Schimmel
First Client Samples
First client samples run on the Global Discovery Panel, investigating coronary artery disease in human plasma samples. From day one our technology was focused on driving our understanding into human health.
Achieved Identification of Over 500 Metabolites In Plasma
Including identification of novel microbial derived metabolites in human plasma, leading our understanding of the importance of our microbiome in our health and wellness and driving early insights into previously unknown gene function through extensive Genome-Wide Association Studies (GWAS).
Achieved Identification of Over 2000 Metabolites In Plasma:
Driven by early adoption of advanced software and instrumental technologies to deliver the most impactful data possible.
Rohan F. Hastie Ph.D. appointed President and CEO
“We envision shaping metabolomics into one of the most valuable technologies impacting life sciences research, drug discovery and development, diagnostics, wellness and therapy response.”
Metabolon Collaborates with Cleveland Clinic to Support Drug Development Research
Metabolon will leverage its leading technology to analyze a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and accelerate clinical trials.
Metabolon Announces Joint Development Agreement with Mayo Clinic
Metabolon and Mayo Clinic will collaborate on a series of investigations on metabolite biomarkers, starting with indicators of inflammatory bowel disease and non-alcoholic fatty liver disease (NAFLD). Additional future collaboration areas to include research into biomarkers revealing the presence of Alzheimer’s disease, pancreatic cancer, breast cancer, inflammatory arthritis, and others.
Metabolon's Platform And Services Are Cited In More Than 3,000 Peer-reviewed Publications
Publications referencing Metabolon, its platform and results have appeared in world-renowned, high-impact journals such as Nature, Nature Medicine, Nature Genetics, Cell, Proceedings of the National Academy of Sciences (PNAS), and many others, demonstrating the dramatic increase in awareness and recognition of the importance of metabolomics in research.
Metabolon Unveils New Integrated Bioinformatics Platform
Metabolon’s new bioinformatics platform alleviates much of the manual data analysis burden associated with interpreting complex biological data. With client data pre-populated and ready for analysis, accelerating discovery with publication-ready charts, plots, data tables, and biological insights at your fingertips.
Metabolon Introduces Multiomic Integration Capabilities
Metabolon announces new multiomics biomarker discovery capabilities within the Integrated Bioinformatics Platform. This new functionality includes multiomics predictive modeling, latent factor analysis, multiomics pathway analysis using public tools like Reactome, and sophisticated multiomic data visualization resources, all to drive the holistic understanding of the study data.
What We Do
Metabolon powers scientific breakthroughs that shape the future of biopharma, public health, consumer wellness, agriculture, and academic research. Our work enables a deeper understanding of complex disease biology, driving the development of transformative treatments that improve lives worldwide. With scalable, customizable solutions, we support the entire research journey—from discovery through clinical trials to commercial success and lifecycle management.
High-Quality Data
Metabolomics Services
Metabolon offers a full suite of metabolomics services designed to support research at every stage—from broad discovery to precise quantification. Our industry-leading Global Discovery Panel delivers untargeted metabolomics with unmatched coverage, identifying up to 5,400 annotated analytes across diverse biological samples, and 2000 qualified unknowns expanding our coverage into the dark metabolome. For more focused needs, our targeted metabolomics platforms include over 150 validated methods, enabling absolute quantification of more than 1,000 metabolites and lipids across key biochemical pathways. Together, these services empower researchers with high-quality, actionable data to drive discoveries in basic science, clinical studies, and translational research.
Meaningful Insights
Integrated Bioinformatics
Metabolon’s Integrated Bioinformatics Platform (IBP) transforms complex biological data into meaningful discoveries. It features industry-standard statistical and visualization tools, such as PCA, PLS-DA, and clustering, to help researchers uncover group differences, reveal molecular drivers, and interpret high-dimensional data with confidence. Designed for multiomics integration, the IBP unifies metabolomic, genomic, transcriptomic, proteomic, phenotypic, and microbiome data to deliver the most holistic view of the biological phenotype. Advanced capabilities like predictive modeling, pathway enrichment via Reactome, and DIABLO-based correlation analysis empower users to explore biomarkers and biological pathways across omics layers. Combined with expert scientific interpretation and a code-free, user-friendly interface, the platform ensures every dataset delivers clear, actionable insights.
Metabolon by Numbers
Explore the key metrics that showcase our contribution to groundbreaking research and data-driven discovery.
1,800,000+
Samples Analyzed
25
Years Experience
4,000+
Publications
45
Employees with PhDs
5,400+
Metabolites In Our Library
15,000+
Completed Projects
Leadership Team
Meet our leadership team that combines scientific expertise, innovative thinking, and a commitment to excellence to shape the future of Metabolon.
Rohan (Ro) F.Hastie, Ph.D.
Karl Bradshaw, Ph.D.
Celia Reyes
Sean Iverson, MBA, MA
Tom Houseman
Michael Irwin
Drew Messick
Thought Leadership
Explore insights from Metabolon’s leadership team, where scientific expertise, innovative thinking, and a commitment to excellence come together to share perspectives shaping the future of metabolomics.
Our Team, Our Values
Our team works tirelessly every day to enable scientific discoveries that make a difference. We are committed to hard work, excellence, and success through collaboration at every level. Our shared devotion to being the best at what we do to make a positive difference unites the contribution of every individual. These are the characteristics of our values: Purpose, Performance, and Passion.
Annie Evans
“Metabolon has truly supported me throughout my career and given me opportunities to grow. When I first started at Metabolon I was running and maintaining the instruments, now I’m leading a team and contributing to our scientific strategy”
Metabolon Named a Great Place To Work®
At Metabolon, we believe in a supportive workplace that values and invests in our associates. Our employees believe in our technology and mission to provide metabolomics solutions that advance a wide variety of applications. We are proud to be certified as a Great Place to Work® for 2023-2024 achieving an 83% rating from employees which is 26% higher than the US-based average.
GET STARTED
Talk with an expert
Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.
Find us on:
